Safety of various parameter sets with navigated microsecond pulsing laser in central serous chorioretinopathy.
CSCR
Navigated microsecond pulsing laser
Safety
Subthreshold
Journal
International journal of retina and vitreous
ISSN: 2056-9920
Titre abrégé: Int J Retina Vitreous
Pays: England
ID NLM: 101677897
Informations de publication
Date de publication:
16 Oct 2021
16 Oct 2021
Historique:
received:
22
05
2021
accepted:
04
10
2021
entrez:
17
10
2021
pubmed:
18
10
2021
medline:
18
10
2021
Statut:
epublish
Résumé
Subthreshold microsecond pulsing laser is an increasingly common treatment approach for central serous chorioretinopathy. However, there is no literature available on the safety of microsecond laser using different fluence settings in this disease. While many publications can be obtained from conventional microsecond pulsing lasers, few parameter sets are published with the navigated microsecond pulsing laser. Therefore, this study aims to investigate the safety of different parameter sets in subthreshold microsecond pulsing laser treatments. In this retrospective chart review, consecutive patients with central serous chorioretinopathy (> 3 months duration of symptoms) treated with navigated subthreshold microsecond pulsing laser and a follow up of at least five months after microsecond laser application were included. For each patient, the treatment parameters, plan layout, and adverse events related to laser were evaluated. Secondary outcomes included best-corrected visual acuity and anatomical improvements (central retinal thickness). One hundred and one eyes were included in the observation and followed for a mean of 10 months (range 5-36). Although a larger range of parameter sets and fluence settings have been used, no patient demonstrated adverse events from navigated microsecond pulsing laser. While 88% of the cases demonstrated stability, 13 cases lost five or more letters due to the persistence of the subretinal fluid. In mean, a best-corrected visual acuity improvement of 0.07logMar (± 0.2) was seen (p = 0.02). In 51% of the patients, a statistically significant improvement of the central retinal thickness was noted at the last follow-up with a mean thickness reduction of 70 µm (± 143) (p < 0.01). In conclusion, none of the used parameter sets lead to tissue damage (when using a cautious titration) and, in summary, lead to an improvement in subretinal fluid and improvement in visual acuity. However, further prospective studies are needed to correctly identify the dependency of the treatment strategy on the outcome criteria.
Sections du résumé
BACKGROUND
BACKGROUND
Subthreshold microsecond pulsing laser is an increasingly common treatment approach for central serous chorioretinopathy. However, there is no literature available on the safety of microsecond laser using different fluence settings in this disease. While many publications can be obtained from conventional microsecond pulsing lasers, few parameter sets are published with the navigated microsecond pulsing laser. Therefore, this study aims to investigate the safety of different parameter sets in subthreshold microsecond pulsing laser treatments.
METHODS
METHODS
In this retrospective chart review, consecutive patients with central serous chorioretinopathy (> 3 months duration of symptoms) treated with navigated subthreshold microsecond pulsing laser and a follow up of at least five months after microsecond laser application were included. For each patient, the treatment parameters, plan layout, and adverse events related to laser were evaluated. Secondary outcomes included best-corrected visual acuity and anatomical improvements (central retinal thickness).
RESULTS
RESULTS
One hundred and one eyes were included in the observation and followed for a mean of 10 months (range 5-36). Although a larger range of parameter sets and fluence settings have been used, no patient demonstrated adverse events from navigated microsecond pulsing laser. While 88% of the cases demonstrated stability, 13 cases lost five or more letters due to the persistence of the subretinal fluid. In mean, a best-corrected visual acuity improvement of 0.07logMar (± 0.2) was seen (p = 0.02). In 51% of the patients, a statistically significant improvement of the central retinal thickness was noted at the last follow-up with a mean thickness reduction of 70 µm (± 143) (p < 0.01).
CONCLUSION
CONCLUSIONS
In conclusion, none of the used parameter sets lead to tissue damage (when using a cautious titration) and, in summary, lead to an improvement in subretinal fluid and improvement in visual acuity. However, further prospective studies are needed to correctly identify the dependency of the treatment strategy on the outcome criteria.
Identifiants
pubmed: 34656180
doi: 10.1186/s40942-021-00335-3
pii: 10.1186/s40942-021-00335-3
pmc: PMC8520234
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62Informations de copyright
© 2021. The Author(s).
Références
Br J Ophthalmol. 2018 Dec;102(12):1696-1700
pubmed: 29439089
Eur J Ophthalmol. 2008 Nov-Dec;18(6):934-40
pubmed: 18988165
BMC Ophthalmol. 2019 Jul 25;19(1):160
pubmed: 31345183
Oman J Ophthalmol. 2018 Sep-Dec;11(3):200-206
pubmed: 30505108
Eye (Lond). 2020 Sep;34(9):1592-1599
pubmed: 31784704
Clin Ophthalmol. 2015 Dec 03;9:2277-83
pubmed: 26664043
Adv Ther. 2017 Jul;34(7):1528-1555
pubmed: 28540655
Trials. 2015 Sep 21;16:419
pubmed: 26390920
Clin Ophthalmol. 2016 Aug 11;10:1513-9
pubmed: 27570446
Semin Ophthalmol. 2003 Sep;18(3):147-53
pubmed: 15513476
Clin Exp Optom. 2011 Jan;94(1):43-51
pubmed: 21039846
Eur J Ophthalmol. 2021 May;31(3):1254-1260
pubmed: 32290705
Cell Biochem Biophys. 2015 Nov;73(2):545-552
pubmed: 27352351
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4722-4732
pubmed: 28910825
Eye (Lond). 2015 Feb;29(2):258-64; quiz 265
pubmed: 25613846
Br J Ophthalmol. 2021 Apr;105(4):555-560
pubmed: 32532761
Eye (Lond). 2016 Oct;30(10):1371-1377
pubmed: 27391938
J Clin Med. 2020 Oct 26;9(11):
pubmed: 33114519
Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2129-35
pubmed: 25717024
Can J Ophthalmol. 1992 Aug;27(5):243-4
pubmed: 1393811
Retina. 2014 Jan;34(1):87-97
pubmed: 23873164
Ophthalmic Res. 2014;51(4):204-9
pubmed: 24685719
Transl Vis Sci Technol. 2020 Apr 28;9(5):23
pubmed: 32821495
Invest Ophthalmol Vis Sci. 2012 Oct 09;53(11):7019-25
pubmed: 22956609
Ophthalmic Surg Lasers Imaging Retina. 2017 Nov 1;48(11):902-905
pubmed: 29121359
Graefes Arch Clin Exp Ophthalmol. 2017 Dec;255(12):2299-2306
pubmed: 28831603
J Ophthalmol. 2015;2015:729792
pubmed: 26697211
Int J Ophthalmol. 2014 Aug 18;7(4):673-6
pubmed: 25161941
Ophthalmology. 2018 Oct;125(10):1547-1555
pubmed: 29776672
Case Rep Ophthalmol Med. 2015;2015:813414
pubmed: 26180649